Chinese Decheng Capital and consortium invested $120 million in California genetics firm
Decheng Capital, a China healthcare investment firm, and a group of other investors announced investment of $120 million in San Francisco genetics firm Invitae.
Invitae is a genetic information company and has raised a total of $207 million from investors to date. It provides a single diagnostic test comprising over 200 genes for $1,500. Decheng Capital, based in Shanghai, provides capital to early and growth stage life science companies and already has stakes in other firms like GeneWeave, GenapSys, SentreHeart, 3SBio, Shenzhen GeneMDx Biotech and SINO Medical Sciences.
To see listing and email addresses of investors from China similar to Decheng Capital, check the Chinese Investors Directory
More details follows
Investors Directory 2022
